Quick Answer
PALVELLA THERAPEUTICS, INC. reported Diluted EPS of $3.71 per share (loss) for fiscal year 2025.
PALVELLA THERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.71 | +52.6% |
| 2024 | -$7.83 | -460.8% |
| 2023 | $2.17 | +405.6% |
| 2021 | -$0.71 | -4.4% |
| 2020 | -$0.68 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.03 | +73.9% | -19.8% |
| June 30, 2025 | -$0.86 | +65.2% | -16.2% |
| March 31, 2025 | -$0.74 | +51.9% | +81.2% |
| September 30, 2024 | -$3.94 | +54.7% | -59.5% |
| June 30, 2024 | -$2.47 | -168.2% | -60.4% |
| March 31, 2024 | -$1.54 | — | +82.3% |
| September 30, 2023 | -$8.70 | — | -340.3% |
| June 30, 2023 | $3.62 | +2685.7% | +2685.7% |
- PALVELLA THERAPEUTICS, INC. showed an increase of +52.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, PALVELLA THERAPEUTICS, INC.’s diluted eps has declined by 445.6% (from $0.68 per share (loss) to $3.71 per share (loss)).
- The most recent figure is from PALVELLA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: